Approaches to interpret the outcomes of a network meta-analysis on comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy
Rama Jayaraj,1 Chellan Kumarasamy,2 Shanthi Sabarimurugan,3 Suja Samiappan41College of Health and Human Sciences, Charles Darwin University, Casuarina, Northern Territory 0909, Australia; 2University of Adelaide, Adelaide, South Australia 5005, Australia; 3School of Biosciences and Technology, Vello...
Main Authors: | Jayaraj R, Kumarasamy C, Sabarimurugan S, Samiappan S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-04-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/letter-comparative-efficacy-of-different-targeted-therapies-plus--peer-reviewed-article-CMAR |
Similar Items
-
A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
by: Xu L, et al.
Published: (2018-11-01) -
Current feasibility of endocrine therapy for breast cancer
by: I. V. Vysotskaya
Published: (2014-07-01) -
Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis
by: Zhang T, et al.
Published: (2018-11-01) -
Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer
by: H. Hawle, et al.
Published: (2010-04-01) -
Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence
by: Rocca A, et al.
Published: (2018-08-01)